{
  "report_rows": [
    {
      "kpi": "Q2 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.32 vs. cons $4.26",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$6.26B vs. cons $6.18B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 organic revenue growth",
      "prediction": "BEAT",
      "answer": "pred ~5.7% vs. cons 5.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 adjusted EPS midpoint",
      "prediction": "BETTER",
      "answer": "guide ~$15.05 vs. cons $14.89 (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 organic revenue growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.0% vs. cons 7.0% (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Second-half organic operating leverage",
      "prediction": "BETTER",
      "answer": "guide ~27% vs. cons 26% (2H26)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.4,
  "day5_path": "FADE",
  "day5_rationale": "The likely EPS raise is partly Q2 beat flow-through: a ~$15.05 FY26 midpoint less predicted Q1\u2013Q2 EPS of ~$6.95 implies ~$8.10 for 2H26 versus roughly $8.00 embedded in prior consensus. That supports modest revisions, but limited out-period upside, premium valuation and peer margin concerns should fade part of the initial relief rally.",
  "day5_confidence": "MEDIUM"
}